Skip to main content
Erschienen in: Wiener klinische Wochenschrift 19-20/2018

03.09.2018 | original article

Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer

verfasst von: Katrin Hefler-Frischmuth, M.D., Christoph Grimm, Lisa Gensthaler, Elisabeth Reiser, Richard Schwameis, Lukas A. Hefler

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2018

Einloggen, um Zugang zu erhalten

Summary

Background

Preoperative hyponatremia and thrombocytosis are associated with perioperative morbidity in patients with epithelial ovarian cancer (EOC). The aim of the present study was to evaluate preoperative hyponatremia and thrombocytosis as prognostic parameters in patients with EOC.

Methods

In a retrospective cohort study, serum levels of sodium and thrombocyte counts were evaluated in 498 patients with EOC. Data were extracted from the prospectively maintained database. Results were correlated with clinicopathological parameters and patient survival.

Results

Mean (standard deviation) overall pretherapeutic serum sodium levels and thrombocyte counts in patients with EOC were 138.8 (2.9) mmol/l and 340.1 (122.6) × 103/µl, respectively. Hyponatremia (serum sodium levels ≤ 134 mmol/l) was found in 33 (6.7%) patients and thrombocytosis (thrombocytes ≥ 450/µl) in 88 (17.7%) patients. Serum sodium levels were associated with the presence or absence of residual tumor tissue after primary surgery. Thrombocyte counts were associated with Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) tumor stage, presence/absence of residual tumor, histological grade and histological type. Patients with thrombocytosis presented with advanced tumor stage, a higher rate of postoperative residual tumor mass, higher tumor grade, and a higher rate of serous ovarian cancer. In a multivariate logistic regression analysis, only the established clinicopathological parameters but not serum sodium and thrombocyte count were independent predictors of patient overall survival.

Conclusion

Preoperative hyponatremia and thrombocytosis are not useful as additional independent prognostic parameters in patients with EOC.
Literatur
1.
Zurück zum Zitat Martin JY, Goff BA, Urban RR. Preoperative hyponatremia in women with ovarian cancer: an additional cause for concern? Gynecol Oncol. 2016;142(3):471–6.CrossRef Martin JY, Goff BA, Urban RR. Preoperative hyponatremia in women with ovarian cancer: an additional cause for concern? Gynecol Oncol. 2016;142(3):471–6.CrossRef
2.
Zurück zum Zitat Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138(3):560–5.CrossRef Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138(3):560–5.CrossRef
3.
Zurück zum Zitat Cozzi GD, Samuel JM, Fromal JT, Keene S, Crispens MA, Khabele D, et al. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer. 2016;16:612.CrossRef Cozzi GD, Samuel JM, Fromal JT, Keene S, Crispens MA, Khabele D, et al. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer. 2016;16:612.CrossRef
4.
Zurück zum Zitat Hoorn EJ, Zietse R. Diagnosis and treatment of Hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28:1340–9.CrossRef Hoorn EJ, Zietse R. Diagnosis and treatment of Hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28:1340–9.CrossRef
5.
Zurück zum Zitat Henry DA. In the clinic: Hyponatremia. Ann Intern Med. 2015;163:ITC1–ITC19.CrossRef Henry DA. In the clinic: Hyponatremia. Ann Intern Med. 2015;163:ITC1–ITC19.CrossRef
6.
Zurück zum Zitat Choi JS, Bae EH, Ma SK, Kweon SS, Kim SW. Prognostic impact of hyponatraemia in patients with colorectal cancer. Colorectal Dis. 2015;17:409–16.CrossRef Choi JS, Bae EH, Ma SK, Kweon SS, Kim SW. Prognostic impact of hyponatraemia in patients with colorectal cancer. Colorectal Dis. 2015;17:409–16.CrossRef
7.
Zurück zum Zitat Schutz FA, Xie W, Donskov F, McDermott DF, Rini BI, Agarwal N, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol. 2014;65(4):723–30.CrossRef Schutz FA, Xie W, Donskov F, McDermott DF, Rini BI, Agarwal N, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol. 2014;65(4):723–30.CrossRef
8.
Zurück zum Zitat Kobayashi N, Usui S, Yamaoka M, Suzuki H, Kikuchi S, Goto Y, et al. The influence of serum sodium concentration on prognosis in resected non-small cell lung cancer. Thorac Cardiovasc Surg. 2014;62(4):338–43.PubMed Kobayashi N, Usui S, Yamaoka M, Suzuki H, Kikuchi S, Goto Y, et al. The influence of serum sodium concentration on prognosis in resected non-small cell lung cancer. Thorac Cardiovasc Surg. 2014;62(4):338–43.PubMed
9.
Zurück zum Zitat Balachandran K, Okines A, Gunapala R, Morganstein D, Popat S. Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer. 2015;15:163.CrossRef Balachandran K, Okines A, Gunapala R, Morganstein D, Popat S. Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer. 2015;15:163.CrossRef
10.
Zurück zum Zitat Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017;8(12):18640–56.CrossRef Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017;8(12):18640–56.CrossRef
11.
Zurück zum Zitat Zwakman N, van de Laar R, Van Gorp T, Zusterzeel PL, Snijders MP, Ferreira I, et al. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. J Gynecol Oncol. 2017;28:e7.CrossRef Zwakman N, van de Laar R, Van Gorp T, Zusterzeel PL, Snijders MP, Ferreira I, et al. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. J Gynecol Oncol. 2017;28:e7.CrossRef
12.
Zurück zum Zitat Luo Y, Kim HS, Kim M, Lee M, Song YS. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis. J Gynecol Oncol. 2017;28:e36.CrossRef Luo Y, Kim HS, Kim M, Lee M, Song YS. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis. J Gynecol Oncol. 2017;28:e36.CrossRef
13.
Zurück zum Zitat Huo J, Hu J, Liu G, Cui Y, Ju Y. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Arch Gynecol Obstet. 2017;295(2):459–65.CrossRef Huo J, Hu J, Liu G, Cui Y, Ju Y. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Arch Gynecol Obstet. 2017;295(2):459–65.CrossRef
14.
Zurück zum Zitat Menczer J. Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. Arch Gynecol Obstet. 2017;295(1):9–15.CrossRef Menczer J. Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. Arch Gynecol Obstet. 2017;295(1):9–15.CrossRef
15.
Zurück zum Zitat Beyazit F, Ayhan S, Celik HT, Gungor T. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet. 2015;292(2):415–20.CrossRef Beyazit F, Ayhan S, Celik HT, Gungor T. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet. 2015;292(2):415–20.CrossRef
16.
Zurück zum Zitat Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Goldstein BH. The impact of total parenteral nutrition on postoperative recovery in patients treated for advanced stage ovarian cancer. Arch Gynecol Obstet. 2017;295(2):439–44.CrossRef Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Goldstein BH. The impact of total parenteral nutrition on postoperative recovery in patients treated for advanced stage ovarian cancer. Arch Gynecol Obstet. 2017;295(2):439–44.CrossRef
17.
Zurück zum Zitat Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127–34.CrossRef Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127–34.CrossRef
Metadaten
Titel
Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer
verfasst von
Katrin Hefler-Frischmuth, M.D.
Christoph Grimm
Lisa Gensthaler
Elisabeth Reiser
Richard Schwameis
Lukas A. Hefler
Publikationsdatum
03.09.2018
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-018-1388-y

Weitere Artikel der Ausgabe 19-20/2018

Wiener klinische Wochenschrift 19-20/2018 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month

mitteilungen der gesellschaft der ärzte in wien

mitteilungen der gesellschaft der ärzte in wien